SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000940397-19-000009
Filing Date
2019-08-07
Accepted
2019-08-07 14:45:39
Documents
5
Group Members
ABUSE DETERRENT PHARMACEUTICAL, INC.

Document Format Files

Seq Description Document Type Size
1 ACURA PHARMACEUTICALS SC13DA-1 acurasc13dajuly2019.htm SC 13D/A 94457
2 EXHIBIT 99.4 acurasc213daex99-4.htm EX-99 47494
3 EXHIBIT 99.5 acuraex99-5.htm EX-99 54073
4 EXHIBIT 99.6 acuraex99-6.htm EX-99 4576
5 ACURA EXHIBIT 99.7 acuraex99-7.htm EX-99 6963
  Complete submission text file 0000940397-19-000009.txt   208955
Mailing Address 616 N. NORTH COURT, SUITE 120 . PALATINE IL 60067
Business Address 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067 847-705-7709
ACURA PHARMACEUTICALS, INC (Subject) CIK: 0000786947 (see all company filings)

IRS No.: 110853640 | State of Incorp.: NY | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-78982 | Film No.: 191004979
SIC: 2834 Pharmaceutical Preparations

Mailing Address 9707 SHELBYVILLE ROAD LOUISVILLE KY 40233
Business Address
Schutte John (Filed by) CIK: 0001713580 (see all company filings)

Type: SC 13D/A